SER J.C., a minor v. Hon. James P. Mazzone, Judge

772 S.E.2d 336, 235 W. Va. 151, 2015 W. Va. LEXIS 259
West Virginia Supreme Court·Decided April 10, 2015·No. 14-1189·Published·Cited by 6 cases

Opinions

LOUGHRY, Justice:

The petitioners1 seek a writ of prohibition to prevent the Mass Litigation Panel from enforcing its order entered on October 21, 2014, dismissing them on the basis of forum non conveniens from the underlying personal injury litigation, which involves products liability and negligence claims. Following a careful review of the briefs, the arguments of counsel, the record submitted, and the applicable law, we deny the requested writ.

I. Facts and Procedural Background

This litigation commenced on July 11, 2012, when a complaint alleging products liability and negligence claims was filed in the Circuit Court of Wayne County by nineteen unrelated mothers, who brought claims on behalf of their respective minor children. The mothers alleged that their ingestion of the drug sertraline hydrochloride, also known by its brand name Zoloft,2 during their pregnancies caused their children to suffer birth defects. Out of this group of nineteen, there is one plaintiff family from each of the following states: Connecticut, Maryland, Michigan, New York, Ohio, Oklahoma, Oregon, South Carolina, Texas, Tennessee, and West Virginia — and two plaintiff families from each of the following states: Florida, Louisiana, North Carolina, and Pennsylvania. The respondents, Pfizer, Inc., Roerig, a division of Pfizer, Inc., and Green-stone, LLC, a subsidiary of Pfizer, Inc., which distributes Zoloft (collectively referred to as “the respondents” or “Pfizer”), were named as defendants in the complaint.

On August 7, 2012, the respondents removed eighteen of these nineteen plaintiff families3 to the United States District Court for the Southern District of West Virginia on the basis of diversity jurisdiction.4 The plaintiff families’ motion to remand was granted by the federal court.5 The respondents appealed that ruling to the United States Court of Appeals for the Fourth Circuit. On July 12, 2013, the Fourth Circuit refused the appeal on the basis that it did “not have the authority” to review the remand order.6

[154]*154Thereafter, the respondents filed a motion seeking to refer the litigation to the Mass Litigation Panel (“the Panel”).7 By administrative order entered on September 24, 2013, then-Chief Justice Benjamin denied the motion -“without prejudice to renew the motion in the event additional state actions [were] filed.”8 On the heels of this denial, a virtually identical complaint was filed in the Wayne County Circuit Court on October 28, 2013, by six unrelated plaintiff families against Pfizer. These six new plaintiff families are residents of Illinois, Indiana, Iowa, New York, South Carolina, and .West Virginia. The circuit court entered an order the same day consolidating the two civil actions.

With two civil actions now pending, the twenty-five plaintiff families filed a motion seeking to refer the litigation to the Panel. While that motion was pending, the respondents filed a second notice of removal in federal court naming all nineteen of the original plaintiff families. Asserting that the New York family omitted from the first removal had been fraudulently joined, the respondents argued there was complete diversity among the remaining eighteen plaintiff families.9 Prior to the entry of the federal court order that would,' again, grant the plaintiff families’ motion to remand,10 then-Chief Justice Davis transferred the two civil actions to the Panel through an administrative order entered on January 14, 2014.11

Following this referral, the Panel held a status conference on March 4, 2014, in what is now known as In re: Zoloft Litigation (“Zoloft litigation”). During this conference, the Panel advised the parties that under Rule 3(a) of the West Virginia Rules of Civil Procedure, the two complaints were actually twenty-five civil actions. Accordingly, the Panel divided the plaintiff families into twenty-five civil actions in an order entered on March 11, 2014. Those families sought a writ of prohibition in this Court to prevent the enforcement of the Panel’s order. On May 27, 2014, this Court issued its opinion in State ex rel. J.C. v. Mazzone, 233 W.Va. 457, 759 S.E.2d 200 (2014) (“Mazzone I ”), wherein it granted the writ of prohibition.

' In Mazzone I, this Court addressed the issue of whether Rule 3(a) allowed the Panel to divide the unrelated plaintiff families into twenty-five separate civil actions, or whether the rule was merely an administrative tool for circuit court clerks to charge unrelated plaintiffs separate filing fees. In addressing this issue, we held, as follows:

[155]*155Rule 3(a) of the West Virginia Rules of Civil Procedure provides that “[f]or a complaint naming more than one individual 'plaintiff not related by marriage, a derivative or fiduciary relationship, each plaintiff shall be assigned a' separate civil action number and be docketed as a separate civil action and be charged a separate fee by the clerk of a circuit court.” Rule 3(a) is an administrative fee and record keeping provision. The use of multiple case docket numbers is for the purpose of assessing and tracking filing fees, and for tracking documents that may apply to individual plaintiffs. Rule 3(a) does not provide authority for severing a complaint substantively into two or more separate civil cases.

Id., at 459, 759 S.E.2d at 202, syl. pt. 3. We further stated in Mazzone I that while the parties were permissibly joined under Rule 20 of the West Virginia Rules of Civil Procedure,

nothing prevents the Panel from using procedural mechanisms to procedurally divide the plaintiffs and defendants into any number of relevant groups, so long as no substantive division occurs---- Moreover, to the extent that some plaintiffs, may be subject to dispositive motions based upon such issues as statutes, of limitation or summary judgment, the Panel also is free to devise a scheme that permits the defendants to raise those issues and have them addressed separately. In addition to these examples, the Panel also may craft solutions to address other procedural issues that may arise.

233 W.Va. at 474, 759 S.E.2d at 217. The Zoloft litigation was remanded to the Panel.

On June. 24, 2014, the Panel entered a Case Management Order12 scheduling various hearings, setting a trial date, and establishing deadlines, including a July 9, 2014, deadline for Rule 12 motions to dismiss. The petitioners did not raise an objection to the Case Management Order, generally, nor to the Rule 12 deadline, specifically.

In conformity with the deadline set forth in the Case Management Order, the respondents filed a motion on July 9, 2014, seeking to dismiss twénty-two non-resident plaintiff families13

Free access — add to your briefcase to read the full text and ask questions with AI

SER J.C., a minor v. Hon. James P. Mazzone, Judge, 772 S.E.2d 336, 235 W. Va. 151, 2015 W. Va. LEXIS 259 (W. Va. 2015).

772 S.E.2d 336 (SER J.C., a minor v. Hon. James P. Mazzone, Judge) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related